Summary of Key Information:

Reporting Period: Quarter ended June 30, 2026 (Q1 FY27)

Nature of Filing / Announcement: Outcome of Board Meeting - Unaudited Financial Results and Director Appointment

Audit Opinion:

Clean/Unmodified - The statutory auditors issued limited review reports with unmodified conclusion on both standalone and consolidated financial results.

Key Financial Highlights [in ₹ Lakh]:

Standalone Results:

Revenue from Operations: 2,215.85 (Q1 FY26: 1,633.64, +35.6% YoY)

Total Income: 2,303.47 (Q1 FY26: 1,739.57)

Net Profit: 386.18 (Q1 FY26: 210.53, +83.4% YoY)

EPS (Basic): 3.65 (Q1 FY26: 2.00)

EPS (Diluted): 3.55 (Q1 FY26: 1.98)

Other Equity: Not specified for quarter

Consolidated Results:

Revenue from Operations: 2,855.76 (Q1 FY26: 2,074.69, +37.6% YoY)

Total Income: 2,951.75 (Q1 FY26: 2,429.23)

Net Profit: 513.72 (Q1 FY26: 443.61, +15.8% YoY)

  • Attributable to Owners: 500.97
  • Attributable to Non-Controlling Interests: 12.75

EPS (Basic): 4.73 (Q1 FY26: 4.08)

EPS (Diluted): 4.65 (Q1 FY26: 4.04)

Other Equity: 11,823.21 (as of March 31, 2026)

Expenses Analysis (Standalone):

Cost of Materials Consumed: 907.36

Employee Benefits Expense: 365.67 (includes ESOP expense of 29.70)

Finance Costs: Not specified for quarter

Depreciation and Amortisation: 90.30

Other Expenses: 424.13

Tax Expenses (Standalone):

Current Tax: 95.81

Deferred Tax: 33.00

Taxation adjustment of earlier years: (2.90)

Segment-wise Performance:

Not Specified - The Group's business activity falls within a single operating segment "Pharmaceutical and Healthcare."

Corporate Actions:

Dividend: Not Specified

Share Allotment: The Company allotted 2,67,250 equity shares of ₹1 each fully paid on exercise of stock options by employees under ESOP Scheme, 2019. Outstanding options as at June 30, 2026: 22,36,250.

Other Significant Information:

Exceptional Items: None for current quarter. Previous year had exceptional items related to implementation of New Labour Codes (₹215.55 lakh standalone, ₹248.71 lakh consolidated).

ESOP Expense: Employee Benefit Expenses includes Share Based Payment expense of ₹29.70 lakh for ESOP Scheme, 2019 (Q1 FY26: ₹14.01 lakh).

Consolidation: Financial results include subsidiaries Kremoint Pharma Private Limited, Eipii Exports Private Limited, Bliss GVS International Pte. Ltd., Asterisk Lifesciences (GH) Limited, Theralife Pharma Ltd, Theralife Pharma RDC Private Limited, and Asterisk Lifesciences Limited.